The value of the Van Nuys prognostic index in ductal carcinoma in situ of the breast: A retrospective analysis

Breast Journal

Volumn 13, Issue 4, 2007, Pages 359-367

  Asjoe, Fernando Tjin ^a   Altintas, Sevilay ^a   Huizing, Manon T ^a   Colpaert, Cecile ^a   Marck, Erik Van ^a   Vermorken, Jan B ^a   Tjalma, Wiebren A ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Ductal carcinoma in situ; Prognostic factors; Van Nuys Prognostic Index

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR VOLUME; VAN NUYS PROGNOSTIC INDEX;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 34250844308     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00443.x     Document Type: Article

References (37)

1. Rosner D, Bedwani RN, Vanna J. Non invasive breast cancer: result of a national survey by the American College of Surgeons. Ann Surg 1980 192: 139 47.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. Ca Cancer J Clin 2001 51: 15 36.
3. Lagios MD. Ductal carcinoma in situ: pathology and treatment. Surg Clin North Am 1990 70: 853 71.
4. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998 16: 441 52.
5. Julien JP, Bijker N, Fentiman IS, et al. Radiation therapy in breastconserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase 3 trial 10853. EORTC Breast cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000 355: 528 33.
6. Bartelink H, Horiot JC, Poortmans P. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. NEJM 2001 345: 1378 87.
7. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001 19: 2263 71.
8. Fisher ER, Dignam J, Tan-Chiu E, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999 86: 429 38.
9. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001 28: 400 18.
10. George WD, Houghton J, Cuzick J, et al. Radiotherapy and tamoxifen following complete local excision in the management of ductal carcinoma in situ: preliminary results from the UK DCIS trial. Proc Am Soc Clin Oncol 2000 19: 70A.
11. Houghton J, UK Coordinating Committee on Cancer Research (UKCCCR). Ductal carcinoma in situ Working Party on behalf of DCIS trialists in the UK, Australia and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, New Zealand: Randomised controlled trial. Lancet 2003 362: 95 102
12. Tjalma WA. Radiotherapy and Tamoxifen in women with completely excised ductal carcinoma in situ. Lancet 2003 362: 1156 57.
13. Poller DN, Snead DR, Roberts EC, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast; relationship to flowcytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 1993 68: 156 61.
14. Bur ME, Zimarowski MJ, Scnitt SJ, et al. Oestrogen receptors immunohistochemistry in carcinomas in situ of the breast. Cancer 1992 69: 1174 81.
15. Malafa M, Chauduri B, Thomford NR, et al. Oestrogen receptors in ductal carcinoma in situ of the breast. Am Surg 1990 56: 436 39.
16. Chauduri B, Crist KA, Mucci S, et al. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 1993 113: 134 7.
17. Zhang Z, Yamashita H, Toyama T, et al. Semi-quantitative immunohistochemical analysis of aromatase-expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2002 74: 47 53.
18. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996 77: 2267 74.
19. Silverstein MJ, Lagios MD, Craig PH, et al. The Van Nuys Prognostic Index for ductal carcinoma in situ. Breast J 1996 2: 38 40.
20. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma in situ treated with breast conserving therapy. J Clin Oncol 2000 18: 296 306.
21. Szelei-Stevens KA, Kuske RR, Yantsos VA, et al. The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiationtherapy or by mastectomy. Int J Radiat Oncol Biol Phys 2000 48: 943 9.
22. Goldstein NS, Vicini FA, Kestin LL, et al. Differences in the pathologic features of ductal carcinoma in situ of the breast based on patients age. Cancer 2000 88: 2553 60.
23. Silverstein MJ. The University of California/Van Nuys Prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003 186: 337 43.
24. Frank HA, Hall FM, Steer ML. Preoperative localization of non palpable breast lesions demonstrated by mammography. NEJM 1976 295: 259 60.
25. Tavassoli FA. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 1998 11: 140 54.
26. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast conserving surgery and definitive breastirradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996 14: 754 63.
27. Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected ductal carcinoma in situ. Frequency of local recurrence following tylectomie and prognostic effect of nuclear grade on local recurrence. Cancer 1989 63: 618 24.
28. Silverstein MJ, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice. Cancer 1990 66: 102.
29. Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993 71: 2532.
30. Boyages J, Delaney G, Taylor R, et al. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999 85: 616.
31. Solin LJ, McCormick B, Recht A, et al. Mammographically detected clinically occult ductal carcinoma in situ treated with breast conserving surgery and definitive breast irradiation. Cancer J Sci Am 1996 2: 158 65.
32. Silverstein MJ, Lagios MD, Groshens S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. NEJM 1999 340: 1455 61.
33. Faverly DR, Burgers L, Bult P, et al. Three-dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994 11: 193.
34. Solin LJ, Fourquet A, Vicini FA, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patients age and margin status. Int J Radiation Oncol Biol Phys 2001 50: 991 1002.
35. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer 1999 86: 990 6.
36. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with micro invasion? Ann Surg Oncol 2000 7: 636 42.
37. Lindsey H. DCIS treatment varies across USA. Lancet Oncol 2004 5: 263.